Abstract
Immune checkpoint inhibitor (ICI) administration represents relatively new modality of cancer therapy that is increasingly used in the treatment of many malignancies, as its administration significantly improves survival of the patients. However, ICI administration may lead to several side effects, including cardiotoxic, with the most common and severe manifestation being the subject of this review, ICI-associated myocarditis.
Although ICI-associated myocarditis has a low incidence, its mortality is high, reaching almost 50%. It is therefore important to be aware of the existence of ICI-associated myocarditis, its clinical manifestations, timely diagnosis, and early administration of immunosuppressive treatment with high-dose corticoids representing the first-line therapy.